APR 22, 2016 12:16 PM PDT

Monocyte-Based Cell Therapy to Treat Macrophage Malfunction

WRITTEN BY: Kara Marker
Macrophages exist in every type of body tissue, in the lungs as alveolar macrophages and in the liver as Kupffer cells. With an incredible ability to specialize in function and a large self-maintenance capacity, it is easy to see how genetic or autoimmune predispositions to macrophage error could quickly result in a terrible, debilitating state of disease.
 
Macrophages engulf and destroy dead and dying cells as well as any pathogens that cross their path. These immune cells differentiate from monocytes early in their life and receive tissue-specific signals depending on the influence of their embryonic precursor. Some monocytes remain forever-young, circulating the blood waiting for an emergency call where they might be needed as back-up. Circulating monocytes do respond to recruiting signals when a tissue is under an uncontrollable amount of duress, but their differentiation into tissue-specific macrophages in response to the call only exists as ephemeral reinforcement.
 
"Macrophage Engulfing Bacteria, Artwork" by David Mack
 
Macrophages were discovered for the first time in 1882, and scientists are only now fully understanding the relationship between adult circulating monocytes and their tissue-specific relatives. In a series of studies published in both Immunity and Nature Communications, scientists from the Flanders Interuniversity Institute for Biotechnology and UGent showed using mouse models how adult circulating monocytes could exist alongside tissue-specific macrophages as equals if exposed to the right signals.
 
While the scientists involved in this study are still unsure about the nature of the signals required for monocytes to differentiate into permanent tissue-specific macrophages, they are hopeful that their discoveries could soon be used as monocyte-based treatments for diseases like pulmonary alveolar proteinosis (PAP), a rare blood disease characterized by malfunctioning of macrophages in the lungs.
 
PAP exists in three forms: congenital, secondary, and acquired, also known as idiopathic or primary. While different forms of the disease are characterized by different causative agents, the disease ultimately remains the same. Phospholipids and protein build up in the alveoli causing severe breathing problems and lung failure.
 
A large majority of PAP cases are acquired, a form of the disease caused by an autoimmune response where antibodies target a blood protein called granulocyte-macrophage colony stimulating factor for destruction. Instead of employing immunosuppressant drugs to halt the autoimmune response, monocyte-based therapy could be incorporated to refuel the lung’s population of macrophages.
 
Using mouse models, scientists involved in the present studies depleted the population of embryonic-derived Kupffer cells in the liver. Miraculously, blood monocytes rushed in to take the place of these macrophages, differentiating and appearing identical to the original macrophage population within two weeks.
 
Similarly, researchers saw both adult circulating monocytes and embryonic precursors differentiate into identical, tissue-specific macrophages when each population was injected into mice lungs lacking alveolar macrophages. The differentiated macrophages remained functional, self-maintained, and preventing disease for up to one year.
 
According to Nature Reviews Immunology, macrophages are “remarkably plastic and can change their functional phenotype depending on the environmental cues they receive.” Martin Guilliams, PhD, one of the scientists involved in the studies, realized the future ability of researchers to manipulate populations of tissue macrophages to treat diseases like PAP.
 
“These findings would predict the existence of a restricted number of macrophage niches per tissue,” he said.
 
Whether it’s curing PAP or another macrophage-associated disease, the future of monocyte-based therapy is extremely promising, especially since circulating monocytes are easily accessible from blood donations, while embryonic precursors to tissue-specific macrophages are not.
 

Source: Flanders Interuniversity Institute for Biotechnology, Pulmonary Alveolar Proteinosis Foundation, Nature Reviews Immunology, publications in Immunity, Nature Communications, and another in Immunity
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 06, 2020
Cardiology
A New Heart Drug Taken from a Yellow Dye
OCT 06, 2020
A New Heart Drug Taken from a Yellow Dye
Cardiovascular disease is an ever-present issue in the modern world.  One of the most unfortunate cardiovascular ev ...
OCT 15, 2020
Health & Medicine
An Estimated 38 Million People were Exposed to Polluted Wildfire Smoke
OCT 15, 2020
An Estimated 38 Million People were Exposed to Polluted Wildfire Smoke
As wildfires continue to burn record-breaking acreages along the west coast of the United States and inland regions, hos ...
OCT 22, 2020
Cardiology
Using Liposomes to Deliver Repair Packages to the Heart
OCT 22, 2020
Using Liposomes to Deliver Repair Packages to the Heart
The secret to any successful drug is not just its ability to treat a disease but its ability to target the disease exclu ...
OCT 21, 2020
Microbiology
The First Treatment for Ebola is Approved by FDA
OCT 21, 2020
The First Treatment for Ebola is Approved by FDA
Ebola virus can pass from animals to humans, and between people. Rarely, it causes outbreaks but when it does, they can ...
OCT 22, 2020
Microbiology
SARS-CoV-2 Has Multiple Routes Into Cells
OCT 22, 2020
SARS-CoV-2 Has Multiple Routes Into Cells
Since the pandemic virus SARS-CoV-2 emerged on the scene late last year, it's left a trail of devastation around the glo ...
OCT 29, 2020
Cannabis Sciences
Hemp 10 Years from Now
OCT 29, 2020
Hemp 10 Years from Now
The hemp industry has experienced major growth in recent years, largely due to legalization in many US states. Today, th ...
Loading Comments...